Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

I am a physician-scientist focused on researching and treating blood and bone marrow cancers, including acute myeloid leukemia and the chronic myeloproliferative neoplasms polycythemia vera, essential ...

About 5%-6% of people with polycythemia vera develop myelofibrosis within the first 10 years of being diagnosed. Your doctor will start with a physical exam, including a check of your spleen.

Dr Vachhani went over the prognostic models ... you need a transplant," we're still measuring the survival of patients with myelofibrosis on the order of years. Knowing when the sweet-spot time ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical ...

The following is a summary of “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open label, randomized, ...

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.

"There remains a tremendous unmet need in myelofibrosis, as less than half ... eventually stop responding to these treatments," said Dr. Raajit Rampal, Director of the Center for Hematologic ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that, following feedback from the U.S. Food and Drug ...